Targeted cardiometabolic therapeutics
Leveraging scientific insights into the intracellular regulation of cortisol, Sparrow is pioneering a precision approach to cardiometabolic disease. Their lead candidate, clofutriben, is a highly potent HSD-1 inhibitor designed to reduce elevated intracellular cortisol, addressing impaired glucose control in millions of patients with difficult-to-control type 2 diabetes.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account